Country | Study | # Patients | HLA-B27 positive (%) | CRP, mg/dL | BASDAI | BASFI | ASQoL |
---|---|---|---|---|---|---|---|
Argentina | Marengo et al., 2008 [17] | 61 | n/r | n/r | 27.2* (Em) 57.7* (Un) | 40.3* (Em) 53.1* (Un) | 5* (Em) 8* (Un) |
Bellomio et al., 2008 [18] | 405 | 46 | 1.9*b | 4.0 | 3.3 | 5 | |
Buschiazzo et al., 2011 [19] | 402 | 45.3 | n/r | 3.8* | 2.6* | n/r | |
Schneeberger et al., 2015 [21] | 73 | 5 | n/r | n/r | n/r | n/r | |
Sommerfleck et al., 2018 [22] | 86 | n/r | n/r | 3.3 (0 c-m) 4.3 (1–2 c-m) 5.8 (≥3 c-m) | 3.2 (0 c-m) 4.5 (1–2 c-m) 5.2 (≥3 c-m) | n/r | |
Sommerfleck et al., 2018 [23] | 50 | n/r | n/r | 4.1* | 4.2* | 11.2* (PsAQoL) | |
Scarafia et al., 2016 (CA) [24] | 92 | 5.6 | n/r | n/r | n/r | n/r | |
Brazil | Sampaio-Barros et al., 2008 [26] | 1036 | 69.5 | n/r | 4.1 | 4.5 | n/r |
Skare et al., 2012 [27] | 1318 | 72.8 (W) 62.4 (AB) 35 (O) | 9.3 (W)b 9.3 (AB)b 11.2 (O)b | 4.0 (W) 4.3 (AB) 4.4 (O) | 4.4 (W) 4.8 (AB) 4.7 (O) | 7.1 (W) 8.6 (AB) 8.7 (O) | |
Skare et al., 2012 [28] | 1424 | 72.8 (< 40 y) 49.5 (≥40 y) | 10.3 (< 40 y) 8.02 (≥40 y) | 4.15 (< 40 y) 4.47 (≥40 y) | 4.6 (< 40 y) 4.7 (≥40 y) | 7.8 (< 40 y) 7.8 (≥40 y) | |
Duarte et al., 2014 [30] | 1189 | 67.9 | n/r | 4.3 | 4.7 | 7.9 | |
Ribeiro et al., 2018 [31] | 202 | 64.2 | 3.6 (W)b 3.7 (NW)b | 3.6 (W) 3.7 (NW) | 4.5 (W) 4.1 (NW) | 7.9 (W) 6.5 (NW) | |
Simioni et al., 2019 [32] | 85 | 69.2 | 8* | 2.4* | 5.1* | 9.2* | |
Chile | Gutiérrez et al., 2008 [34] | 109 | 66.4 | 16.2b | 4.9 | 4.5 | n/r |
Ibáñez et al., 2019 (CA) [35] | 472 | n/r | n/r | 6.1 | 5 | 10a | |
Colombia | Bautista-Molano et al., 2016 [37] | 581 | 43.9 | 11.7 | 5.4 (Ax) 5.3 (Pr) | n/r | n/r |
Santos et al., 2017 [38] | 189 | 40.7 | n/r | n/r | n/r | n/r | |
Costa Rica | Sáenz Castro et al., 2008 [39] | 33 | 57.1 | 0.6 | 4.6 | 3.9 | n/r |
Mexico | Casasola-Vargas et al., 2008 [40] | 172 | n/r | 12b | 4.5 | 4.0 | n/r |
Peláez-Ballestas et al., 2013 [12] | 28 | 14.3 | n/r | n/r | n/r | n/r | |
Peru | Chávez-Corrales et al., 2008 [41] | 60 | 31 | n/r | n/r | n/r | n/r |
Uruguay | Palleiro and Spangenberg, 2008 [42] | 53 | approx. 50 (AS, uSpA) 14 (PsA) | 6.2 mg/L | 5.3 | 4.3 | n/r |
Venezuela | Chacón et al., 2008 [43] | 69 | n/r | 8.4b | 4.4 | 3.6 | n/r |
Multinational | García-Kutzbach et al., 2011 [44] | 233 | 57.1 (Costa Rica) 29 (El Salvador) 4 (Guatemala)c | n/r | n/r | n/r | n/r |
Benegas et al., 2012 [45] | 1083 | 71 | 10b | 4.3 | 4.8 | 7 | |
Bautista-Molano et al., 2018 [46] | 390 | n/r | n/r | n/r | 3.4 | n/r |